NT219 found to suppress cancer stem cells that promote drug resistance to KRASG12C and KRASG12D inhibitors and solid tumor recurrence Potential biomarkers for treatment with NT219 detected in.
/PRNewswire/ Pomerantz LLP is investigating claims on behalf of investors of D-Wave Quantum Inc. ("D-Wave" or the "Company") (NYSE: QBTS). Such investors.